NasdaqGS - Delayed Quote USD

Bio-Techne Corporation (TECH)

64.06 +1.40 (+2.23%)
At close: April 26 at 4:00 PM EDT
64.06 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
1,144,999.00
1,136,702.00
1,105,599.00
931,032.00
738,691.00
Cost of Revenue
376,362.00
366,887.00
349,103.00
298,182.00
255,497.00
Gross Profit
768,637.00
769,815.00
756,496.00
632,850.00
483,194.00
Operating Expense
507,981.00
478,817.00
460,668.00
390,160.00
334,347.00
Operating Income
260,656.00
290,998.00
295,828.00
242,690.00
148,847.00
Net Non Operating Interest Income Expense
-10,576.00
-7,805.00
-10,515.00
-13,479.00
-18,592.00
Other Income Expense
1,378.00
55,466.00
16,073.00
-81,036.00
146,222.00
Pretax Income
251,458.00
338,659.00
301,386.00
148,175.00
276,477.00
Tax Provision
27,296.00
53,217.00
38,287.00
8,590.00
47,181.00
Net Income Common Stockholders
224,114.00
285,193.00
271,930.00
140,324.00
229,072.00
Diluted NI Available to Com Stockholders
224,114.00
285,193.00
271,930.00
140,324.00
229,072.00
Basic EPS
1.42
1.81
1.73
0.91
1.50
Diluted EPS
1.39
1.76
1.66
0.87
1.46
Basic Average Shares
157,648.50
157,179.00
156,874.00
154,986.00
152,804.00
Diluted Average Shares
161,472.50
161,855.00
164,114.00
161,932.00
157,604.00
Total Operating Income as Reported
268,602.00
298,944.00
296,590.00
237,296.00
157,419.00
Total Expenses
884,343.00
845,704.00
809,771.00
688,342.00
589,844.00
Net Income from Continuing & Discontinued Operation
224,162.00
285,263.00
272,051.00
140,410.00
229,296.00
Normalized Income
218,164.33
237,936.98
259,294.72
217,593.71
108,371.43
Interest Income
3,715.00
3,410.00
794.00
473.00
605.00
Interest Expense
14,291.00
11,215.00
11,309.00
13,952.00
19,197.00
Net Interest Income
-10,576.00
-7,805.00
-10,515.00
-13,479.00
-18,592.00
EBIT
265,749.00
349,874.00
312,695.00
162,127.00
295,674.00
EBITDA
375,986.00
457,112.00
413,764.00
249,874.00
378,411.00
Reconciled Cost of Revenue
376,362.00
291,725.00
280,526.00
238,223.00
199,118.00
Reconciled Depreciation
110,237.00
107,238.00
101,069.00
87,747.00
82,737.00
Net Income from Continuing Operation Net Minority Interest
224,162.00
285,263.00
272,051.00
140,410.00
229,296.00
Total Unusual Items Excluding Goodwill
6,728.00
56,140.00
14,612.00
-81,936.00
145,868.00
Total Unusual Items
6,728.00
56,140.00
14,612.00
-81,936.00
145,868.00
Normalized EBITDA
369,258.00
400,972.00
399,152.00
331,810.00
232,543.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
730.33
8,813.98
1,855.72
-4,752.29
24,943.43
6/30/2020 - 2/9/1989

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PCVX Vaxcyte, Inc.
60.72
+1.10%
 
LEGN Legend Biotech Corporation
45.30
+1.98%
 
GMAB Genmab A/S
28.15
+2.51%
 
ARGX argenx SE
372.80
+1.14%
 
ASND Ascendis Pharma A/S
135.90
-0.75%
 
UTHR United Therapeutics Corporation
233.85
-0.89%
 
RPRX Royalty Pharma plc
28.00
-0.39%
 
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
 
RVMD Revolution Medicines, Inc.
35.96
+1.78%
 
KRYS Krystal Biotech, Inc.
156.88
+0.77%